Standard BioTools Inc (NASDAQ: LAB) kicked off on Friday, down -4.72% from the previous trading day, before settling in for the closing price of $1.06. Over the past 52 weeks, LAB has traded in a range of $0.92-$2.64.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 8.27%. While this was happening, its average annual earnings per share was recorded 55.77%. With a float of $365.87 million, this company’s outstanding shares have now reached $379.09 million.
Considering the fact that the conglomerate employs 818 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 47.04%, operating margin of -82.21%, and the pretax margin is -78.07%.
Standard BioTools Inc (LAB) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Medical Devices Industry. The insider ownership of Standard BioTools Inc is 3.67%, while institutional ownership is 72.28%. The most recent insider transaction that took place on May 23 ’25, was worth 1,344. In this transaction Chief Financial Officer of this company sold 1,428 shares at a rate of $0.94, taking the stock ownership to the 930,286 shares. Before that another transaction happened on May 23 ’25, when Company’s SVP & Chief Business Officer sold 13,217 for $0.94, making the entire transaction worth $12,437. This insider now owns 843,076 shares in total.
Standard BioTools Inc (LAB) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 55.77% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 66.44% during the next five years compared to 11.61% growth over the previous five years of trading.
Standard BioTools Inc (NASDAQ: LAB) Trading Performance Indicators
Take a look at Standard BioTools Inc’s (LAB) current performance indicators. Last quarter, stock had a quick ratio of 5.37. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.26.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.36, a number that is poised to hit -0.07 in the next quarter and is forecasted to reach -0.15 in one year’s time.
Technical Analysis of Standard BioTools Inc (LAB)
Compared to the last year’s volume of 1.71 million, its volume of 1.77 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 69.66%. Additionally, its Average True Range was 0.09.
During the past 100 days, Standard BioTools Inc’s (LAB) raw stochastic average was set at 7.38%, which indicates a significant decrease from 33.33% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 84.72% in the past 14 days, which was lower than the 88.66% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.1148, while its 200-day Moving Average is $1.5833. Nevertheless, the first resistance level for the watch stands at $1.0500 in the near term. At $1.0900, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.1100. If the price goes on to break the first support level at $0.9900, it is likely to go to the next support level at $0.9700. Should the price break the second support level, the third support level stands at $0.9300.
Standard BioTools Inc (NASDAQ: LAB) Key Stats
The company with the Market Capitalisation of 383.62 million has total of 379,822K Shares Outstanding. Its annual sales at the moment are 174,430 K in contrast with the sum of -138,890 K annual income. Company’s last quarter sales were recorded 40,800 K and last quarter income was -26,030 K.
